Skip to main content
About Us

Our Governance

At Chiesi, we take a long-term perspective guided by decades of experience informing how we innovate, operate and create a lasting impact.

This commitment led us to become a Benefit Corporation in Italy in 2018, in accordance with Italian Law No. 208/2015, embedding responsible governance into our business model to strengthen performance across societal, environmental and business measures. Currently, Chiesi has adopted Benefit Corporation legal status in Italy, the United States, France, and Colombia. 

Board of Auditors

Raffaella Pagani

President

Patrizia Arienti

Statutory Auditor

Massimo Livatino

Statutory Auditor

Map of Group Locations 

Alberto Chiesi

Alberto Chiesi

Honorary President

Alberto Chiesi was born in Parma on December 26, 1938. He is married and has two sons. 

Dr. Chiesi took his undergraduate degree in Pharmacy at the University of Parma in 1960/61, and he graduated in Chemistry in 1962/63. 

From 1985 to July 2023, Dr. Alberto served as President of Chiesi Farmaceutici S.p.A. Today the Company counts more than 6,500 employees working in 31 different countries. The Group mainly focuses on the research in the biomedical field in which is invested over the 21.4% of its turnover. 

Since 2001, Dr. Chiesi is the Coordinator of the Italian Group of small-medium Companies of Farmindustria, and since 2005 he holds the position in the Chairman’s Committee. 

In 1993, he has been honoured by the President of the Italian Republic with the title of Cavaliere del Lavoro due to his entrepreneurial activity and his commitment in the field of R&D. 

In 2015, Dr. Alberto together with his brother Paolo, has been awarded by the Ernst & Young as the EY World Entrepreneur of the Year in the field of Healthcare and Life Science. 

In 2016 he has been awarded by the University of Parma with the Honoris Master’s degree in Administration and Management. In 2020 he was named Knight of the Légion d'Honneur, the highest decoration of the French Republic.

In the same year, he was appointed member of the General Council of the Cariparma Foundation.

Maria Paola Chiesi

Maria Paola Chiesi

Chair

Maria Paola holds a Degree in Medicinal Chemistry and Pharmacological Sciences and a Master in Business Administration (MBA).

Since 1995, she has been working at Chiesi Farmaceutici S.p.A., holding various roles in Business Development, Corporate Marketing, and Strategic Planning.

Since 2010, Maria Paola is responsible, first as coordinator and from 2021 as President, for Paolo Chiesi Foundation, a non-profit organization, expression of Chiesi corporate social responsibility, devoted to research and international cooperation projects in the domain of respiratory medicine and neonatology. The main focus of the Foundation is to promote the access to quality neonatal essential care in West Africa.

Since 2015 she has been Director of Shared Value & Sustainability, whose objective is to constantly and rigorously measure and quantify the company’s impacts on the society and the environment, define integrated improvement plans and transparently report the environmental and societal performance.

In July 2023, Maria Paola is appointed Vice Chair of Chiesi Farmaceutici S.p.A.

In 2026, Maria Paola Chiesi is appointed Chair of Chiesi Farmaceutici S.p.A.

She is a Member of the Board of Directors of CEA Parma (Center for Environmental Ethics); President of the Council for Solidarity and Social Cohesion of the Association “Parma per la Famiglia”; President of the KilometroVerdeParma Social Enterprise Forestry Consortium. Maria Paola is also a Professional Coach, Coach Mentor, and Supervisor.

She is married and mother of three children.

Alessandro Chiesi

Alessandro Chiesi

Vice Chair

Alessandro Chiesi was born in Parma on August 7, 1966. He is married and has five children. 

After completing examinations at the faculty of Economics and Commerce at the University of Parma, he starts working in Chiesi Farmaceutici in 1995. 

Alessandro Chiesi contributes to the internationalization process of Chiesi Group, first as M&A responsible, and then as affiliates’ supervisor within the International Division. 

In 2002 Alessandro Chiesi becomes General Manager of the new-born Chiesi Germany and in 2010 he takes the lead of the International Division. 

In 2016 he founds and chairs the “Parma, io ci sto!” Association, which counts, at date, than 135 companies which are committed to work with institutions for the social and economic development of Parma territory. 

From 2020 to July 2023, he held the position of Chief Commercial Officer (CCO) of the Chiesi Group. 

In 2023, Alessandro Chiesi is appointed Chair of Chiesi Farmaceutici S.p.A. 

In 2026, after nearly three years in the role, he completed his tenure and continues to serve as Vice Chair of the Group.

Giacomo Chiesi

Giacomo Chiesi

Board Member

Giacomo Chiesi currently serves as Head of Global Rare Diseases at the Chiesi Group. He is based in Boston, Massachusetts. 

Previously, Giacomo served as Head of Global Corporate Development. In his tenure with the Chiesi Group he has directly structured and executed 25 deals with over $3B in value ranging from sell-side to buy-side M&A, in- and out-licensing, and spin-outs. He serves on the Board of the Company.

In 2014, he founded Chiesi Ventures as a joint venture with Pappas Capital and is the fund Managing Partner. He serves as a Board Member or Observer on the Boards of Sentien Biotech and and Minoryx Therapeutics and was previously on the boards of Glycomine and Aura Bioscience. 

In 2021, he was elected to the board of directors of the Biotechnology Innovation Organisation (BIO), in the Emerging Companies Section (ECS). 

Before going back to the Chiesi Group, Giacomo was a consultant with Bain & Co, where he led teams in a variety of assignments including due diligence, restructuring and strategy projects for consumer goods and information technology companies in different countries. 

Previously he was with Accenture where he led large teams in outsourcing projects across Europe and the US for clients in transportation and retail. 

Giacomo earned a M.Sc. degree Magna cum Laude in Telecommunications Engineering from the University of Parma, Italy, and an MBA from the University of Chicago Booth School of Business with concentrations in Entrepreneurship, Economics and Finance.

Andrea Chiesi

Andrea Chiesi

Board Member

Andrea Chiesi was born in Parma on July 15, 1967. He is married with a daughter. He took his undergraduate degree in Chemistry and Pharmaceutical Technology in 1992. 

Dr. Chiesi started his career in the Company in 1993 as a pharmaceutical technology scientist. In 1997 he became Project Leader and assumed the responsibility of Planning and Control of Research in 1999. 

In 2006 he obtained an Executive MBA at the London Business School and at Columbia University. 

After serving in many operational assignments in the R&D, in 2009 Dr. Chiesi became R&D Portfolio Management Director. 

Until 2019, Dr. Andrea Chiesi has been President of “Arrigo Boito” Music Conservatory of Parma. 

He is Chairman of the Board of Confindustria Emilia Romagna Ricerche and of the cultural Association Footprint and sits on the Board of Prometeo Foundation.

Jean-Marc Bellemin

Jean-Marc Bellemin

Interim Group CEO; Executive Vice President Group CFO

Jean-Marc Bellemin brings over 30 years of international experience in finance, operations, and corporate strategy in the pharmaceutical and biotech sectors.

He has held leadership roles at companies including Actelion Pharmaceuticals, Gritstone Oncology, and Iovance Biotherapeutics, where he served as Chief Financial Officer and played a central role in financing strategy, corporate growth, and global commercialization efforts.

Jean-Marc joined Chiesi Group in July 2025 as Group Chief Financial Officer and member of the Group Executive Leadership Team, contributing to the company’s financial strategy, operations management, and long-term business planning. Since 15 May 2026, he has also served as Interim CEO.

Jean-Marc holds a Bachelor of Science in Economics and Management from Paris Dauphine University, a Master’s in Finance and Accounting from Paris Sorbonne University, and an MBA from ESSEC Business School.

He also completed the General Management Program at Harvard Business School.

Roch Doliveux

Roch Doliveux

Independent Non-Executive Director

Dr. Roch Doliveux has extensive leadership experience in biopharmaceuticals, having held both executive and non-executive positions across various companies. 

Between 1990 and 2003 Dr Doliveux held various roles at Schering-Plough (now Merck Inc.) successively as General Manager in Belgium and Luxembourg, Vice President and General Manager France, Senior Vice President Managed Care US and President International. 

In 2003 Doliveux was named as Chief Executive Officer of Pharmaceuticals at Pierre Fabre. 

Between 2003 and 2014, Dr Doliveux held various roles at UCB, first as Director General of Pharmaceuticals and then Chief Executive Officer as of 2004. Between 2010 and 2014, he was also member of the Board and then Chair of IMI, the largest public private partnership in the world for Biopharmaceutical Research. 

Subsequently, he held various non-executive directorships, including serving as member of the Board of UCB, Chair of Remuneration Committee of the Board of Stryker (USA) and Chair of the Board for the Pierre Fabre Group since 2017. Since June 2020, he has been the Chair of the Board at Oxford Biomedica, a company specializing in the development and manufacture of viral vectors for cell and gene therapies. 

Dr Doliveux received his PhD in Veterinary Medicine with honors from École Nationale Vétérinaire d'Alfort, France in 1980. In 1981, he received an MBA from INSEAD with distinction. 

He was bestowed the title of Commander of the Order of the Crown by the Belgian Government in November 2015. Dr Doliveux is a Swiss national.

Paolo Pucci

Paolo Pucci

Independent Non-Executive Director

Paolo Pucci offers Chiesi a wealth of governance experience, having served as a CEO, independent director, and committee member across entities in the US, EU, and Brazil. 

He has served as Non-Executive Director on multiple boards, including Trillium Therapeutics Inc. (NASDAQ:TRIL, acquired by Pfizer in 2021), New Link Genetics Inc, Algeta ASA (Oslo Borse:ALGETA, acquired by Bayer AG in 2014), Dyax Inc. (NASDAQ:DYAX, acquired by Shire in 2016) and currently serves as an independent director Replimune Group Inc. (NASDAQ:REPL), Merus NV (NASDAQ:MRUS) and as Lead Independent Director at West Pharmaceutical Services (NYSE:WST). 

Pucci started his career in industrial chemicals, auditing, and then banking. He worked as Indirect Sales and Marketing Manager at Citibank in Italy, a role he left in 1991. 

He then pivoted to work in pharma and from 1991 and 2001, Pucci took various roles at Eli Lilly & Company Inc. beginning in Italy and subsequently US, France and Sweden. His positions included Marketing Head Central Nervous System for Europe Middle East Africa region, National Sales Manager Diabetology and Endocrinology, and Business Unit Manager Neuroscience. He finished his time at Eli Lilly as Country Head, Sweden. 

Between 2001 and 2008, Pucci took on various roles at Bayer Schering AG, including serving as Country Head Pharmaceuticals Italy and subsequently and simultaneously as a member of the Board of Management Global Pharma, SVP North America Pharma and President Global Specialty Pharmaceuticals. He ended his time at Bayer Schering as SVP and President of the Global Specialty Pharmaceuticals Business Unit based in the U.S. 

Between 2008 and 2020, he was the Chief Executive Officer of ArQule. In this role, Pucci successfully raised approximately $400 million in capital and restructured the company, balancing discovery and clinical development. 

He led the development of a proprietary clinical pipeline featuring several best-in-class compounds in oncology and rare diseases, culminating in the company's sale to Merck (NYSE:MSD) for $2.7 billion in 2020. 

Paolo Pucci graduated from the Università di Napoli, Italy, with a BA in Economics, 1984 and in 1985 obtained license to practice as Dottore Commercialista (Chartered Accountant) in Italy. He finished his studies graduating from the University of Chicago Booth Graduate School of Business with an MBA in 1990. He holds dual American and Italian citizenships.

Daphne Quimi

Daphne Quimi

Independent Non-Executive Director

Daphne Quimi serves on the boards of Amylyx Pharmaceuticals (NASDAQ: AMLX) and Century Therapeutics (NASDAQ: IPSC). She has experience with acquisitions, CEO transitions, and major restructurings. Quimi is the Audit Chair for both companies. 

Her extensive experience in financial management and strategic leadership makes her well-suited to support Chiesi's growth in the United States. Her expertise in corporate governance will be invaluable as Chiesi expands its presence in this critical market. 

Quimi started her career as an auditor at KPMG between 1988 and 1991. From 1991 to 2004 she held several positions at Johnson & Johnson, including Project Manager in Financial Analysis, Manager of Worldwide Finance Procedures, and Director of Consolidations and External Reporting. 

She held the role of Director of Financial Reporting at Bristol-Myers Squibb between 2005 and 2007, as well as taking up the role of Regional Controller, Sarbanes Oxley Compliance, Global Finance at Avon Products between 2004 and 2005. 

Between 2007 and 2024, Quimi worked at Amicus Therapeutics. She started as a Director, External Reporting and Technical Accounting, later taking various roles as a controller. She then became Senior Vice President, Administration and Operations. Following this, she became the Chief Financial Officer between 2019 and 2023, before retiring from Amicus in 2024. 

Quimi holds a BS in Accounting from Monmouth University, USA, which she received in 1988. She later earned a CPA, in New Jersey, USA. She concluded her studies with an MBA in Finance and International Business from New York University, USA in 1999. She is a US citizen.